Evidence map›Paper›PMID 40014905›Full record

ArticleClinics (Sao Paulo, Brazil)2025

Investigating the role of MicroRNA-519d-3p in enhancing chemosensitivity of colorectal cancer cells to 5-Fluorouracil through PFKFB3 targeting.

Yangyang Zhang, Yiqing Zhang, Yanan Xiao, Shufen Xu, Jie Li, Juan Li, Lisha Chang, Jie Ding, Di Wu, Li Wang and 2 more

Abstract read
In one paragraph

Article in Clinics (Sao Paulo, Brazil), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yangyang ZhangDepartment of General Practice, The First Affiliated Hospital with Nanjing Medical University, Nanjing City, Jiangsu Province, PR China; Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing City, Jiangsu Province, PR China.
Yiqing ZhangProfessor, Department of Rehabilitation Medicine Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing City, Jiangsu Province, PR China.
Yanan XiaoDepartment of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing City, Jiangsu Province, PR China.
Shufen XuDepartment of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing City, Jiangsu Province, PR China.
Jie LiDepartment of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing City, Jiangsu Province, PR China.
Juan LiDepartment of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing City, Jiangsu Province, PR China.
Lisha ChangDepartment of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing City, Jiangsu Province, PR China.
Jie DingDepartment of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing City, Jiangsu Province, PR China.
Di WuDepartment of Rehabilitation Medicine Center, Yixing People's Hospital, Yixing City, Jiangsu Province, PR China.
Li WangDepartment of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing City, Jiangsu Province, PR China.
Guangxu XuProfessor, Department of Rehabilitation Medicine Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing City, Jiangsu Province, PR China.
Keming WangDepartment of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing City, Jiangsu Province, PR China. Electronic address: kemingwang@njmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveIn the fight against Colorectal Cancer (CRC), chemotherapy resistance is a major obstacle. Therefore, it is imperative to identify effective biomarker therapeutics. Despite microRNAs (miRs) playing a crucial role in drug resistance, the mechanisms comprising miR-519d-3p's role in CRC drug resistance have not been fully understood. Therefore, the present study aimed to investigate the biological function of miR-519d-3p in the chemosensitivity of CRC cells to 5-Fluorouracil (5-FU).

methodsCRC cells were treated with 5-FU and transfected. Cellular proliferation, invasion, and apoptosis were evaluated. The relationship between miR-519d-3p and 6-Phosphofructokinase-2/Frucose-2, 6-Biphosphatase-3 (PFKFB3) was analyzed, and their interaction in CRC was further investigated. In vivo tumor experiments were conducted to investigate the function of miR-519d-3p and 5-FU in CRC.

resultsAs determined, CRC cells overexpressing miR-519d-3p were more sensitive to 5-FU in vitro, as miR-519d-3p inhibits proliferation and invasion and stimulates apoptosis. miR-519d-3p directly targeted PFKFB3. In CRC cells, PFKFB3 overexpression rescued miR-519d-3p-induced 5-FU toxicity. In vivo results showed that mice co-treated with miR-519d-3p mimics and 5-FU showed higher antitumor activity.

conclusionOverall, it may be possible to improve 5-FU chemosensitivity of CRC cells by targeting miR-519d-3p and PFKFB3.

Indexed as

Antimetabolites, AntineoplasticColorectal NeoplasmsDrug Resistance, NeoplasmFluorouracilMicroRNAsPhosphofructokinase-2AnimalsApoptosisCell Line, TumorCell ProliferationHumansMiceMice, Inbred BALB CMice, NudeAntimetabolites, AntineoplasticFluorouracilMicroRNAsPFKFB3 protein, humanPhosphofructokinase-25-FluorouracilChemosensitivityColorectal CancerMicroRNA-519d-3pPFKFB3Therapeutic Approach

Identifiers

PMID40014905
PMCPMC11910362

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.